AWM
TGTX icon

Abound Wealth Management’s TG Therapeutics TGTX Stock Holding History

Abound Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$193K Hold
3,506
– – 0.04% 101
2026
Q1 		$116K Hold
3,506
– – 0.03% 137
2025
Q4 		$105K Hold
3,506
– – 0.02% 134
2025
Q3 		$127K Hold
3,506
– – 0.03% 113
2025
Q2 		$126K Buy
3,506
+3,498
+43,725% +$130K 0.04% 105
2025
Q1 		$316 Sell
8
-2
-20% -$67 ﹤0.01% 865
2024
Q4 		$301 Hold
10
– – ﹤0.01% 894
2024
Q3 		$234 Buy
+10
New +$218 ﹤0.01% 1076

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Abound Wealth Management's TGTX Position: Q2 2026 in Review

Abound Wealth Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 3,506 shares worth $193K. The position accounts for 0.04% of the portfolio, ranked #101.

Abound Wealth Management first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Abound Wealth Management held 3,506 shares of TG Therapeutics worth $193K as of Q2 2026.
  • Abound Wealth Management left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up 0.04% of Abound Wealth Management's portfolio in Q2 2026, its #101 holding.
  • Abound Wealth Management first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.